1,247 results on '"van Gilst, Wiek H."'
Search Results
2. Pectins from various sources inhibit galectin-3-related cardiac fibrosis
3. Predictors and outcomes of heart failure with mid‐range ejection fraction
4. Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease
5. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
6. The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise
7. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
8. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction
9. Genome-wide association study identifies eight loci associated with blood pressure
10. Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND
11. Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance
12. Hypertrophy induced KIF5B controls mitochondrial localization and function in neonatal rat cardiomyocytes
13. Transitions across Kidney Disease Stages and Association with New-onset Heart Failure: a Population-Based study of 8569 Individuals and 12.6 Years of Follow-up
14. Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH
15. Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study
16. Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial)
17. Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist
18. LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes
19. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
20. Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation
21. Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial
22. β-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial
23. Sex differences in new-onset heart failure
24. Genetic factors in the progression of atherosclerosis and response to cholesterol lowering drugs
25. Coronary Vascular Function in Stable and Unstable Angina
26. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT)
27. Prognostic value of renin and prorenin in heart failure patients with decreased kidney function
28. Experimental and Clinical Cardiac Beta-receptor Studies
29. Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study
30. Studies of cardiac receptors by positron emission tomography
31. Activation of liver X receptor-α reduces activation of the renal and cardiac renin–angiotensin–aldosterone system
32. Erythropoiesis Stimulation in Acute Ischemic Syndromes
33. Qualitative examination of compliance in heart failure patients in The Netherlands
34. Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization
35. Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA)
36. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects
37. Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor
38. Emerging role of liver X receptors in cardiac pathophysiology and heart failure
39. Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction
40. Comparing New Onset Heart Failure with Reduced Ejection Fraction and New Onset Heart Failure with Preserved Ejection Fraction: An Epidemiologic Perspective
41. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
42. Animal models of cardiorenal syndrome: a review
43. Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin
44. Angiotensin-(1–7): Pharmacological properties and pharmacotherapeutic perspectives
45. Erythropoietin in cardiac disease: New features of an old drug
46. Caveolae and endothelial dysfunction: Filling the caves in cardiovascular disease
47. Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation
48. C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: Data from the prospective PREVEND cohort
49. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects
50. Possible Association Between Telomere Length and Renal Dysfunction in Patients With Chronic Heart Failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.